Evolution and innovation in autologous cell therapy supply chain
Cell & Gene Therapy Insights 2021; 7(8), 905–911
Published: 18 August 2021
Sadia L’Baouch has more than 20 years’ experience in manufacturing operations, supply chain management and external supply. She has a successful track record in devising strategy and infrastructures for new products and managing multiple sites. Sadia joined Ixaka from Sangamo Therapeutics where, as Senior Director of Supply Chain and Manufacturing, she managed CMOs for delivery of early phase programs using CAR-Tregs (chimeric antigen receptor regulator T cells). Prior to Sangamo Therapeutics, Sadia spent 17 years at GlaxoSmithKline in roles such as Operations and Supply Director, Director of Manufacturing and Supply, and Supply Chain Senior Director where she led on supply chain for the launch of the first ex vivo gene therapy Strimvelis. She transitioned to Orchard Therapeutics in 2018 following its acquisition of the GSK Rare Diseases portfolio to act as Supply Chain Senior Director. There she continued to manage global supply chain operational aspects for autologous cell and gene therapy products for both clinical and commercial supplies.